Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Ece EsinB OksuzogluA BiliciI CicinO KostekM A KaplanS AksoyB Y AktasO OzdemirA AlacaciogluD CabukA T SumbulA SakinS PaydasE YetisirO ErT KorkmazN YildirimT SakalarH DemirM ArtacM KaraagacH HarputluogluE BilenE ErdurS DegirmenciogluA AliyevT CilP OlgunG BasaranO GumusayA DemirE TanrikuluP F YumukInanc ImamogluB OyanB CetinV HaksoylerN KaradurmusI ErturkT EvrenselH YilmazI BeypinarM KocerK N PilanciM SekerY UrunN YildirimT ErenU Demircinull nullPublished in: Cancer chemotherapy and pharmacology (2018)
Our RLP trial included only visceral metastatic, trastuzumab-naïve BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- end stage renal disease
- squamous cell carcinoma
- healthcare
- clinical trial
- white matter
- insulin resistance
- tyrosine kinase
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase iii
- study protocol
- phase ii
- type diabetes
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- blood brain barrier
- combination therapy
- multiple sclerosis
- stem cells
- metabolic syndrome
- mesenchymal stem cells
- weight loss
- skeletal muscle
- subarachnoid hemorrhage